Challenges in therapy of chronic hepatitis B

Journal of Hepatology

Volumn 39, Issue SUPPL. 1, 2003, Pages

  Hoofnagle, Jay H ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE ANALOG; RECOMBINANT ALPHA INTERFERON;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; CONFERENCE PAPER; DELTA AGENT HEPATITIS; DISEASE ASSOCIATION; DRUG EFFICACY; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; INFECTION PREVENTION; INFECTION RISK; LIVER BIOPSY; LIVER HISTOLOGY; LONG TERM CARE; MAINTENANCE THERAPY; PRIORITY JOURNAL; TREATMENT INDICATION; VIRUS CARRIER; VIRUS DIAGNOSIS; VIRUS MUTANT;

EID: 0141526118     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0168-8278(03)00332-5     Document Type: Conference Paper

References (22)

1. Greenberg HB, Pollard RB, Lutwick LI, Gregory PB, Robinson WS, Merigan TC. Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. N Engl J Med 1976;295:517-522.
2. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000-summary of a workshop. Gastroenterology 2001;120:1828-1853.
3. Manesis EK, Papatheodoridis GV, Hadziyannis SJ. Serum HBV-DNA levels in inactive hepatitis B virus carriers. Gastroenterology 2002;122:2092-2093.
4. Martinot-Peignoux M, Boyer N, Colombat M, Akremi R, Pham BN, Ollivier S, et al. Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers. J Hepatol 2002;36:543-546.
5. Fong TL, Di Bisceglie AM, Gerber MA, Waggoner JG, Hoofnagle JH. Persistence of hepatitis B virus DNA in the liver after loss of HBsAg in chronic hepatitis B. Hepatology 1993;18:1313-1318.
6. Di Bisceglie AM, Waggoner JG, Hoofnagle JH. Hepatitis B virus deoxyribonucleic acid in liver of chronic carriers: correlation with serum markers and changes associated with loss of hepatitis B e antigen after antiviral therapy. Gastroenterology 1987;93:1236-1241.
7. Wong DKH, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1993;119:312-323.
8. Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996;334:1422-1427.
9. Lau D-Y, Everhart J, Kleiner DE, Park Y, Vergalla J, Schmid P, et al. Long-term follow-up of patients with chronic hepatitis B treated with interferon α. Gastroenterology 1997;113:1660-1667.
10. Lok ASF, Chung H-T, Liu VWS, Ma OCK. Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. Gastroenterology 1993;105:1833-1838.
11. Fattovich G, Farci P, Rugge M, Brollo L, Mandas A, Pontisso P, et al. A randomized controlled trial of lymphoblastoid interferon-alfa in patients with chronic hepatitis B lacking HBeAg. Hepatology 1992;15:584-589.
12. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995;333:1657-1661.
13. Lai C-L, Chien R-N, Leung NWY, Chang T-T, Guan R, Tai D-I, et al. A 1-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998;339:61-68.
14. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HWL, Goodman Z, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-1263.
15. Marcellin P, Chang T-T, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al. Adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. N Engl J Med 2003;348:808-816.
16. Hadziyannis S, Tassopolous N, Heathcote E, Chang T-T, Kitis G, Rizzetto M, et al. Adefovir dipivoxil for the treatment of HBeAg-negative chronic hepatitis B. N Engl J Med 2003;348:800-807.
17. Song BC, Suh DJ, Lee HC, Chung Y-H, Lee YS. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000;32:803-806.
18. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DLJ. Mutation in the HBV RNA dependent DNA polymerase confers resistance of lamivudine in vivo. Hepatology 1996;24:714-717.
19. Lau DT-Y, Khokhar F, Doo E, Ghany MG, Herion D, Park Y, et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000;32:838-844.
20. Heathcote E, Jeffers L, Perrillo R, Wright T, Sherman M, Namini H, et al. Sustained antiviral response and lack of viral resistance with long term adefovir dipivoxil (ADV) therapy in chronic HBV infection. J Hepatol 2002;36(Suppl. 1):110. [abstract].
21. Lindsay KL. Therapy of hepatitis C: overview. Hepatology 1997;26(Suppl. 1):71S-77S.
22. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994;95:1513-1520.